Supplementation of fresh ucche (Momordica charantia L. var. muricata Willd) prevented oxidative stress, fibrosis and hepatic damage in CCl4 treated rats

BMC Complementary and Alternative Medicine

Volumn 15, Issue 1, 2015, Pages

  Sagor, Abu Taher ^a   Chowdhury, Mohammed Riaz Hasan ^a   Tabassum, Nabila ^a   Hossain, Hemayet ^b   Rahman, Md Mahbubur ^a   Alam, Md Ashraful ^a  

^a NORTH SOUTH UNIVERSITY   (Bangladesh)

^b BCSIR Laboratories Dhaka   (Bangladesh)

Author keywords

Aminotransferases; Fibrosis; Inflammation; Momordica charantia; Oxidative stress; Reactive oxygen species

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIINFLAMMATORY AGENT; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; CATALASE; GLUTATHIONE; LIPID PEROXIDE; MALONALDEHYDE; MOMORDICA CHARANTIA EXTRACT; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; ANTIOXIDANT; IRON; PLANT EXTRACT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FLUID INTAKE; FOOD INTAKE; HISTOPATHOLOGY; LIPID PEROXIDATION; LIVER FIBROSIS; LIVER FUNCTION; LIVER HOMOGENATE; LIVER INJURY; LIVER PROTECTION; MOMORDICA CHARANTIA; NONHUMAN; OXIDATIVE STRESS; RAT; SUPPLEMENTATION; WEIGHT REDUCTION; ANIMAL; DIET SUPPLEMENTATION; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; INFLAMMATION; LIVER; LIVER CIRRHOSIS; LONG EVANS RAT; METABOLISM; PATHOLOGY; PHYTOTHERAPY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CARBON TETRACHLORIDE; DIETARY SUPPLEMENTS; DRUG-INDUCED LIVER INJURY; FEMALE; GLUTATHIONE; INFLAMMATION; IRON; LIPID PEROXIDATION; LIVER; LIVER CIRRHOSIS; MOMORDICA CHARANTIA; OXIDATIVE STRESS; PHYTOTHERAPY; PLANT EXTRACTS; RATS; RATS, LONG-EVANS; REACTIVE OXYGEN SPECIES;

EID: 84928787043     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/s12906-015-0636-1     Document Type: Article

References (51)

1. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349(5):474-85.
2. Weber LWD, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol. 2003;33(2):105-36.
3. 4-induced acute liver injury of mice. Free Radic Biol Med. 2000;29(9):870-80.
4. He SX, Luo JY, Wang YP, Wang YL, Fu H, Xu JL, et al. Effects of extract from Ginkgo biloba on carbon tetrachloride-induced liver injury in rats. World J Gastroenterol. 2006;12(24):3924-8.
5. Singh N, Kamath V, Narasimhamurthy K, Rajini PS. Protective effect of potato peel extract against carbon tetrachloride-induced liver injury in rats. Environ Toxicol Pharmacol. 2008;26(2):241-6.
6. Ai G, Liu Q, Hua W, Huang Z, Wang D. Hepatoprotective evaluation of the total flavonoids extracted from flowers of Abelmoschus manihot (L.) Medic: in vitro and in vivo studies. J Ethnopharmacol. 2013;146(3):794-802.
7. Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol. 2011;4(6):391-417.
8. 4-treated rats: role of the hepatic endocannabinoid and apelin systems. J Pharmacol Exp Ther. 2011;340(3):629-37.
9. Krawinkel MB, Keding GB. Bitter gourd (Momordica charantia): a dietary approach to hyperglycemia. Nutri Rev. 2006;64(7):331-7.
10. 4 protein in fructose-fed rats. J Ethnopharmacol. 2009;123(1):82-90.
11. Matsui S, Yamane T, Takita T, Oishi Y, Kobayashi-Hattori K. The hypocholesterolemic activity of Momordica charantia fruit is mediated by the altered cholesterol- and bile acid-regulating gene expression in rat liver. Nutri Res. 2013;33:580-5.
12. Shih C-C, Shlau M-T, Lin C-H, Wu J-B. Momordica charantia ameliorates insulin resistance and dyslipidemia with altered hepatic glucose production and fatty acid synthesis and AMPK phosphorylation in high-fat-fed mice. Phytother Res. 2014;28(3):363-71.
13. Thenmozhi AJ, Subramanian P. Antioxidant potential of Momordica Charantia in ammonium chloride-induced hyperammonemic rats. Evidence-Based Complement Alternat Med. 2011, Article ID 612023.
14. Kubola J, Siriamornpun S. Phenolic contents and antioxidant activities of bitter gourd (Momordica charantia L.) leaf, stem and fruit fraction extracts in vitro. Food Chem. 2008;110(4):881-90.
15. Horax R, Hettiarachchy N, Islam S. Total phenolic contents and phenolic acid constituents in 4 varieties of bitter melons (Momordica charantia) and antioxidant activities of their extracts. J Food Sci. 2005;70(4):C275-80.
16. Horax R, Hettiarachchy N, Chen P. Extraction, quantification, and antioxidant activities of phenolics from pericarp and seeds of bitter melons (Momordica charantia) harvested at three maturity stages (immature, mature, and ripe). J Agric Food Chem. 2010;58(7):4428-33.
17. Nakamura S, Murakami T, Nakamura J, Kobayashi H, Matsuda H, Yoshikawa M. Structures of new cucurbitane-type triterpenes and glycosides, karavilagenins and karavilosides, from the dried fruit of Momordica charantia L. in Sri Lanka. Chem Pharm Bull. 2006;54(11):1545-50.
18. Alam MA, Uddin R, Subhan N, Rahman MM, Jain P, Reza HM. Beneficial role of bitter melon supplementation in obesity and related complications in metabolic syndrome. J Lipids. 2015, Article ID 496169.
19. Wu S-J, Ng L-T. Antioxidant and free radical scavenging activities of wild bitter melon (Momordica charantia Linn. var. abbreviata Ser.) in Taiwan. LWT - Food Sci Technol. 2008;41(2):323-30.
20. Niehaus WG, Samuelsson B. Formation of malonaldehyde from phospholipid arachidonate during microsomal lipid peroxidation. Eur J Biochem. 1968;6(1):126-30.
21. Tracey WR, Tse J, Carter G. Lipopolysaccharide-induced changes in plasma nitrite and nitrate concentrations in rats and mice: pharmacological evaluation of nitric oxide synthase inhibitors. J Pharmacol Exp Ther. 1995;272(3):1011-5.
22. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen A, Zingraff J, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996;49:1304-13.
23. Tiwari BK, Kumar D, Abidi AB, Rizvi SI. Efficacy of composite extract from leaves and fruits of medicinal plants used in traditional diabetic therapy against oxidative stress in alloxan-induced diabetic rats. ISRN Pharmacol 2014 Article ID 608590.
24. 4-induced oxidative stress in the thyroid tissue of rats. BMC Complement Alternat Med. 2012;12(1):181.
25. Chance B, Maehly AC. Assay of catalase and peroxidases. Methods Enzymol. 1955;11:764.
26. Jollow D, Mitchell J, Zampaglione N, Gillette J. Bromobenzene-induced liver necrosis: protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacol. 1974;11:151-69.
27. Pierce RA, Glaug MR, Greco RS, Mackenzie JW, Boyd CD, Deak SB. Increased procollagen mRNA levels in carbon tetrachloride-induced liver fibrosis in rats. J Biol Chem. 1987;262(4):1652-8.
28. 4-induced hepatotoxicity: protective effect of rutin on p53, CYP2E1 and the antioxidative status in rat. BMC Complement Alternat Med. 2012;12:178.
29. 4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol. 2008;73(2):399-409.
30. Ching RHH, Yeung LOY, Tse IMY, Sit W-H, Li ETS. Supplementation of bitter melon to rats fed a high-fructose diet during gestation and lactation ameliorates fructose-induced dyslipidemia and hepatic oxidative stress in male offspring. J Nutri. 2011;141(9):1664-72.
31. Szymonik-Lesiuk S, Czechowska G, Stryjecka-Zimmer M, Słomka M, Madro A, Celiński K, et al. Catalase, superoxide dismutase, and glutathione peroxidase activities in various rat tissues after carbon tetrachloride intoxication. J Hepatobiliary Pancreat Surg. 2003;10(4):309-15.
32. 4-induced liver damage in rats. Asian Pac J Trop Biomed. 2014;4(6):480-5.
33. Quan J, Piao L, Wang X, Li T, Yin X. Rossicaside B protects against carbon tetrachloride-induced hepatotoxicity in mice. Basic Clin Pharmacol Toxicol. 2009;105(6):380-6.
34. Nadler EP, Dickinson EC, Beer-Stolz D, Alber SM, Watkins SC, Pratt DW, et al. Scavenging nitric oxide reduces hepatocellular injury after endotoxin challenge. Am J Physiol Gastrointest Liver Physiol. 2001;281(1):G173-81.
35. Chaudhari B, Chaware V, Joshi Y, Biyani K. Hepatoprotective activity of hydroalcoholic extract of Momordica charantia Linn. leaves against carbon tetra chloride induced hepatopathy in rats. Int J ChemTech Res. 2009;1:355-8.
36. 4-induced rat hepatocytes damage; role of Apoptosis and pro-inflammatory cytokines inhibition. Sci Rep. 2014;4:Article number: 5880.
37. Liu C, Tao Q, Sun M, Wu JZ, Yang W, Jian P, et al. Kupffer cells are associated with apoptosis, inflammation and fibrotic effects in hepatic fibrosis in rats. Lab Invest. 2010;90(12):1805-16.
38. Tung BY, Emond MJ, Bronner MP, Raaka SD, Cotler SJ, Kowdley KV. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterol. 2003;124(2):318-26.
39. Purohit V, Russo D, Salin M. Role of iron in alcoholic liver disease: introduction and summary of the symposium. Alcohol. 2003;30(2):93-7.
40. Richards JA, Wigmore SJ, Devey LR. Heme oxygenase system in hepatic ischemia-reperfusion injury. World J Gastroenterol. 2010;16(48):6068-78.
41. Immenschuh S, Baumgart-Vogt E, Mueller S. Heme oxygenase-1 and iron in liver inflammation: a complex alliance. Curr Drug Targets. 2010;11(12):1541-50.
42. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev. 2008;60(1):79-127.
43. He JY, Ge WH, Chen Y. Iron deposition and fat accumulation in dimethylnitrosamine-induced liver fibrosis in rat. World J Gastroenterol. 2007;13(14):2061-5.
44. Arezzini B, Lunghi B, Lungarella G, Gardi C. Iron overload enhances the development of experimental liver cirrhosis in mice. Int J Biochem Cell Biol. 2003;35(4):486-95.
45. Houglum K, Ramm GA, Crawford DH, Witztum JL, Powell LW, Chojkier M. Excess iron induces hepatic oxidative stress and transforming growth factor beta1 in genetic hemochromatosis. Hepatol. 1997;26(3):605-10.
46. De Minicis S, Marzioni M, Saccomanno S, Rychlicki C, Agostinelli L, Trozzi L, et al. Cellular and molecular mechanisms of hepatic fibrogenesis leading to liver cancer. Transl Gastrointest Cancer. 2011;1(1):88-94.
47. Pietrangelo AGR, Casalgrandi G, Geerts A, De Bleser P, Montosi G, Ventura E. Enhanced hepatic collagen type I mRNA expression into fat-storing cells in a rodent model of hemochromatosis. Hepatol. 1994;19(3):714-21.
48. Lee C-C, Shen S-R, Lai Y-J, Wu S-C. Rutin and quercetin, bioactive compounds from tartary buckwheat, prevent liver inflammatory injury. Food & Function. 2013;4(5):794-802.
49. Ambrose SS, Solairaj P, Subramoniam A. Effectiveness of ellagic acid on isoniazid-rifampicin induced liver damage in rats. J Pharmacol Pharmacother. 2013;4(1):60-2.
50. Girish C, Pradhan SC. Drug development for liver diseases: focus on picroliv, ellagic acid and curcumin. Fund Clin Pharmacol. 2008;22(6):623-32.
51. Chang CJ, Tzeng T-F, Liou S-S, Chang Y-S, Liu I-M. Myricetin increases hepatic peroxisome proliferator-activated receptor-α, protein expression and decreases plasma lipids and adiposity in rats. Evid Based Complementary Altern Med. 2012 Article ID 787152.